Abstract
Chronic infection with human cytomegalovirus (CMV) may contribute to poor vaccine efficacy in older adults. We assessed effects of CMV serostatus on antibody quantity and quality, as well as cellular memory recall responses, after 2 and 3 SARS-CoV-2 mRNA vaccine doses, in older adults in assisted living facilities. CMV serostatus did not affect anti-Spike and anti-RBD IgG antibody levels, nor neutralization capacity against wildtype or beta variants of SARS-CoV-2 several months after vaccination. CMV seropositivity altered T cell expression of senescence-associated markers and increased TEMRA cell numbers, as has been previously reported; however, this did not impact Spike-specific CD4+ T cell memory recall responses. CMV seropositive individuals did not have a higher incidence of COVID-19, though prior infection influenced humoral immunity. Therefore, CMV seropositivity may alter T cell composition but does not impede the durability of humoral protection or cellular memory responses after SARS-CoV-2 mRNA vaccination in older adults.
Key Points CMV seropositive older adults have more EMRA and terminally differentiated T cells CMV seropositivity does not prevent antibody maintenance after SARS-CoV-2 vaccination CMV seropositivity does not impede SARS-CoV-2 vaccine T cell memory recall responses
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the COVID-19 Immunity Task Force of the Public Health Agency of Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Hamilton Integrated Research Ethics Board of McMaster University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: The authors have no financial relationship with any organization that may have an interest and have no other relationships or activities that could pose a conflict of interest.
Funding: This work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada awarded to Costa and Bowdish. APC is the Schlegel Chair in Clinical Epidemiology and Aging. DMEB is the Canada Research Chair in Aging & Immunity. Funding support for this work was provided by grants from the Ontario Research Foundation COVID-19 Rapid Research Fund, and by the Canadian COVID-19 Immunity Task Force awarded to IN. MSM is supported, in part, by an Ontario Early Researcher Award and a Canada Research Chair in Viral Pandemics.
Figure order and layout has been revised to better present the data. Text has been added to the Methods and Results to provide further information on the study cohort, sample collection time points, and to clarify protocols to determine prior SARS-CoV-2 infection.
Data Availability
Data are not available without prior approval from the Hamilton Integrated Research Ethics Board (HiREB).
